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Abstract 
 
Objective: To determine whether dosage adjustment of enoxaparin during pregnancy, in order to 
maintain a peak anti-Xa of 1.0-1.2 U/ml, is safe for women with mechanical prosthetic heart 
valves (MPHV).  
 
Methods: This was a prospective observational study performed at Charlotte Maxeke 
Johannesburg Academic Hospital from 2007 to 2009. 15 women with MPHVs were treated with 
enoxaparin with dosage adjustment throughout pregnancy to achieve a peak anti-Xa of 1.0-1.2 
U/ml. Main outcomes measured were prosthetic valve thrombosis, bleeding and maternal 
mortality.  
 
Results: There was no maternal mortality. None of the women developed valvular thrombosis 
during pregnancy. Two women developed epistaxis and another developed spotting per vagina. 
There was no foetal mortality. 
 
Conclusion: Our data show that enoxaparin may be administered safely during pregnancy to 
pregnant women with mechanical prosthetic heart valves when there is dosage adjustment 
throughout pregnancy in order to maintain an anti-Xa of 1.0-1.2 U/ml.  
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Introduction: 
 
Physiological adaptation to pregnancy is the most rapid and profound change that a woman’s 
body undergoes in her life time. One of the changes that occur is the generation of a state of 
hypercoagulability. This thrombogenicity is due to a number of reasons, such as changes 
affecting the coagulation factors, the rate of blood flow and the development of endothelial 
damage. Levels of coagulation factors such as factors VII, VIII, X and fibrinogen increase as 
pregnancy progresses, peaking at delivery
1
. Factors II, V and IX remain essentially stable 
throughout pregnancy. Markers of thrombin (Factor IIa) generation, such as prothrombin 
fragments 1 and 2, as well as thrombin-antithrombin complexes are also elevated during 
pregnancy
2
. In addition fibrinolysis is suppressed in the second and third trimesters of pregnancy 
due to elevated levels of plasminogen activator inhibitor type 1 (PAI-1), which may increase 
fivefold, and to increased levels of PAI-2 which is produced by the placenta and has peak 
concentrations produced in the third trimester
2, 3
. Maximal suppression of fibrinolysis occurs 3 
hours post delivery
3
. Similarly levels of soluble, active and unbound, protein S decrease as the 
pregnancy progresses with the lowest levels being recorded an hour post delivery 
4
. Other 
reasons that predispose pregnant women to thrombosis include the reduction in venous flow in 
pregnancy and the trauma to the endothelium of the pelvic veins which occurs at delivery. The 
hypercoagulable state begins to revert back to the pre-pregnancy state hours after delivery but 
only fully returns to normal about six weeks post delivery
3, 4
. Notable physiological changes 
occurring in other systems in pregnancy include changes in the cardiovascular and genitourinary 
and systems.  
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Cardiovascular changes include an enlarged circulatory volume, a rise in the cardiac output and a 
drop in blood pressure. Circulatory volume changes comprise an increased red cell volume 
(about 20%) and an increased plasma volume (about 40%). Cardiac output rises in the first 
trimester as a result of an increased heart rate and stroke volume. The heart rate and stroke 
volume increase as a compensatory response to a drop in the systemic vascular resistance which 
in turn is caused by peripheral vasodilation occurring in pregnancy. The heart rate increases by 
up to 20% in the third trimester, and the stroke volume begins to increase at 8 weeks of gestation, 
reaching a plateau by 16-20 weeks gestation. The cardiac output rises to 30-50% of non-pregnant 
values, peaking at the end of the second trimester. Despite the increased cardiac output in the 
first trimester, the blood pressure still falls due to the low systemic vascular resistance. The 
blood pressure falls by 10% at the 8
th
 week of gestation and reaches its lowest level at 24 weeks 
gestation and then rises to normal pre-pregnancy levels by term. The cardiac output increases at 
the onset of labour then drops rapidly postpartum
5
. In the third stage of labour fluid shifts occur 
resulting in an increased venous return to the heart. This involves the addition of about 500ml of 
blood from the uterus into the peripheral circulation, the removal of the compression of the 
inferior vena cava by the gravid uterus and fluid shifts from the extravascular to the intravascular 
space. The changes put a strain on the heart but this only results in cardiac decompensation when 
the cardiac function is already compromised.   
 
Genitourinary system changes include an increase in the renal plasma flow rate at the end of the 
first trimester resulting in an increased glomerular filtration rate of about 50%. This increased 
glomerular filtration rate is maintained until the 36
th
 week, dropping down towards pre-
pregnancy levels thereafter
6
.  
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The prevalence of rheumatic heart disease (RHD) is significantly higher in developing countries 
than in developed countries with quoted prevalence rates being 100-200 times greater
7
. The 
current prevalence of RHD in South Africa is unknown however a survey conducted in Soweto 
in 1975 showed the prevalence to be 6.9/1000
8
. For this reason RHD is a common underlying 
cause of cardiac disease in pregnancy in South Africa despite it being a preventable disease. 
RHD accounted for 63.5% of all recorded maternal cardiac disease at Pretoria Academic 
Hospital between 2002 and 2005
9
. RHD is a common indication for mitral or aortic valve 
replacement. Options for valve replacement include either a bioprosthetic valve or a mechanical 
prosthetic heart valve (MPHV). Bioprosthetic valves, despite having the significant advantage 
over mechanical prosthetic heart valves of not requiring thromboprophylaxis during pregnancy
10
, 
are not ideal for young females of child bearing age. This is because porcine bioprosthetic valves 
have been associated with a high rate of structural valvular damage (SVD) with a 10 year 
survival rate of 50%
10,11
. Pregnancy has been shown to accelerate the rate of SVD with damage 
occurring in 10-35% of such pregnancies
12,13,14
 and reoperation mortality is quoted as 3,8% in 
one study
15
 and 8,7% in another
16
. Furthermore one study, done in a South African population, 
showed that patients with mechanical prosthetic heart valves are able to cope well with the 
cardiac demands of pregnancy
17
 and other studies have shown these valves to have excellent 
long term durability
18
. For these reasons mechanical prosthetic heart valves are still in use and 
are commonly used in young women especially in developing countries. Mechanical prosthetic 
heart valves are of three main types: the cage-ball valves such as the Starr-Edwards valve, the 
tilting disc valves, such as the Bjork-Shiley and the Medtronic valves, and the bileaflet valves 
such as the St Jude’s Medical valve. Compared to the bioprosthetic valves however, mechanical 
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prosthetic heart valves require long term anticoagulation due to their increased thrombogenicity. 
Greater thrombogenicity is associated with the older generation valves (Starr-Edwards and 
Bjork-Shiley) compared to the newer generation valves (St Jude’s Medical and Medtronic) and 
with a prosthetic valve in the mitral as opposed to the aortic position
19
.  
 
Patients with mechanical prosthetic heart valves who fall pregnant are at an even greater risk of 
thromboembolic disease. The options available for anticoagulation during pregnancy may 
however be associated with significant foetal and maternal morbidity and mortality. Risks of 
treatment include the teratogenicity of the oral anticoagulant warfarin, and the possibility of 
treatment failure of unfractionated heparin (UFH) and Low Molecular Weight Heparin (LMWH) 
resulting in maternal valvular thrombosis. Furthermore there is a risk of excessive bleeding with 
any of the aforementioned options.  
 
When it occurs, prosthetic valve thrombosis may be a fatal complication. Symptoms include (of) 
acute dyspnoea and chest pain which may often be retrosternal or subscapular and orthopnoea. 
Typical signs include muffled prosthetic valve heart sounds on auscultation, particularly 
muffling of the opening snap, or there may be absence of prosthetic valve sounds altogether
20
 in 
the clinical setting of congestive cardiac failure. Clinical features of peripheral arterial 
thromboembolic disease, such as cerebrovascular accidents and transient ischaemic attacks, may 
also be a feature of valvular thrombosis. The diagnosis is confirmed by fluoroscopy, and 
echocardiography which may be either trans-thoracic or ideally trans-oesophageal.  
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Warfarin therapy throughout pregnancy is believed to be most efficacious in the prevention of 
the maternal thromboembolic disease for patients with mechanical prosthetic heart valves. 
Unfortunately evidence has shown that this drug may be associated with foetal morbidity and 
mortality described in the literature as “warfarin embryopathy”21. The incidence of warfarin 
embryopathy has been shown to be highest between the sixth and twelfth week of gestation
21
. 
The documented incidence of warfarin embryopathy has been a subject of much debate. 
Estimates have ranged from as low as 1,6%
 22
 to 6,4%
 23
. A recent authoritative text has however, 
suggested that such figures probably represent an underestimation given the retrospective nature 
of the reports and the lack of pathological assessment of the aborted foetuses of most series
24
. 
This is supported by a prospective study in which reported facial defects suggestive of warfarin 
embryopathy accounted for 29% of viable offspring
25
. Oral anticoagulants have a molecular 
weight of approximately 1 000 and readily cross the placenta to the foetus. Therapeutic doses for 
the mother will unfortunately result in a considerable overdose for the foetus due to the 
immaturity of foetal liver enzyme systems and the low levels of vitamin K – dependent clotting 
factors
26
. The features associated with warfarin embryopathy due to warfarin exposure during the 
1
st
 trimester include spontaneous abortions, still births, facial abnormalities such as nasal 
hypoplasia, and chondrodysplasia punctata
23
.  Chondrodysplasia punctata is diagnosed by 
observing epiphyseal calcification on X-rays of the new born, also called epiphyseal stippling. 
Warfarin blocks the regeneration of reduced vitamin K by inhibiting vitamin K epoxide 
reductase. Vitamin K is an essential cofactor for post translational carboxylation of glutamic acid 
residues of osteocalcin and matrix glutamic acid protein, which modulate calcium deposition. 
This failure of synthesis of osteocalcin and glutamic acid matrix protein results in epiphyseal 
stippling and nasal hypoplasia
27
.  Stippling occurs primarily in the axial skeleton at the proximal 
13 
 
femurs and in the calcanei. This may result in scoliosis
21
.  Central nervous system abnormalities 
and eye abnormalities are also noted and are likely to be due to warfarin exposure in the second 
and third trimesters
21
. Central nervous system abnormalities include an increased risk of a low 
intelligence quotient (below 80) with a relative risk quoted as
 
7.6
28
.  Eye abnormalities such as 
micropthalmia optic atrophy and blindness have been reported
21
. Despite its teratogenic effects, 
and primarily due to its proven efficacy in prevention of maternal valvular thrombosis, warfarin 
is still recommended by some authors as one of the options for prophylactic anticoagulation for 
higher risk pregnancies, such as those pregnant women with a first generation prosthetic heart 
valve in the mitral position
19
. The high risk of serious foetal abnormalities due to warfarin 
therapy highlights the need for alternative therapies to be sought for this patient group. 
 
UFH is an alternative therapy in women who elect to avoid treatment with warfarin, especially 
during the first trimester. However two retrospective surveys conducted in Europe and a 
prospective study performed in Mexico reported a high incidence of valve thrombosis in 
pregnant women with old-generation mechanical prosthetic heart valves treated with fixed or 
adjusted dose subcutaneous UFH
12,29,30
. Although the clinical implications of these findings are 
questionable
31, owing to lack of information related to the level of anticoagulation and it’s 
monitoring. Unfortunately, the efficacy of adjusted-dose subcutaneous heparin has not been 
definitively established
32
. The use of the APTT to determine UFH dosing is problematic for 
these patients for a number of reasons. Inherent limitations in using the APTT include the fact 
that the manufactured UFH polysaccharide chains consist of varying lengths hence introducing 
subtle variation between the effects of different vials used for the patient; there is nonspecific 
binding of UFH to plasma proteins in vivo with large inter-patient variability in the total protein 
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concentration; the normal range of the APTT is wide introducing a possible bias in the 
determination of a baseline control value required to adjust the patient’s dose of UFH, and the 
ability of UFH to inactivate both factors IIa and Xa results in a less specific action of UFH
33,34
. 
These factors may have contributed to a less predictable anticoagulant response resulting in the 
treatment failures associated with UFH. Additional documented side effects of UFH include the 
serious complication of heparin induced thrombocytopaenia
35
 and osteoporosis. It is estimated 
that approximately 30% of pregnant women receiving long term UFH therapy will lose 10% of 
their bone mass and 2% will have symptomatic vertebral fracture
36,37
.  
  
LMWHs are glycosaminoglycan molecules which exert their anticoagulant activity by binding to 
antithrombin and causing a conformational change that greatly enhances the ability of 
antithrombin to bind to and inhibit the action of the activated coagulation factor X (factor Xa). 
The LMWHs have generated a significant amount of interest in recent years; the reason for this 
is twofold. Firstly, the improved pharmacokinetics and side effect profile of the LMWHs 
compared to UFH and secondly, the potential benefits in pregnancy. LMWHs have been shown 
to cause less heparin induced thrombocytopaenia than UFH. As LMWH’s have a smaller average 
molecular weight (of about 5 000) in comparison to UFH (average molecular weight of 12 000 to 
15 000), LMWH’s have a higher specificity for inhibition of activated factor X (factor Xa) via 
antithrombin, as opposed to the inhibition of activated factor II (factor IIa). Due to the higher 
molecular weight of UFH there is a greater frequency of sugar chains comprised of at least 13 
sugars bound to the specific pentasaccharide sequences required to induce inactivation of factor 
IIa via antithrombin in comparison to LMWH. In addition a study performed in pregnancy 
showed that LMWH usage was associated with significantly less osteoporosis when compared to 
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UFH usage
38
. A study done in 44 pregnant women showed that the bone mineral density 
measured in the patients who received LMWH was significantly higher than those who received 
UFH
39
. A number of studies done on LMWH use in pregnancy show that the LMWHs are 
generally safe when administered for thromboprophylaxis in pregnancy
40
. Because the average 
molecular weight of LMWH is 5000 it has been shown not to cross the placenta, hence its use in 
pregnancy is safe for the foetus
41
.   
 
LMWH therapy monitoring is achieved by anti factor Xa (anti Xa) monitoring
42
. Two kinds of 
laboratory test are in use. These are the chromogenic and the clotting based anti Xa assays. Of 
the two assays consensus guidelines recommend the chromogenic assay for LMWH 
monitoring
43
. The principle of the chromogenic anti-Xa test is as follows. Factor X is initially 
activated in vitro by thromboplastin and calcium mediated activation of the coagulation cascade. 
A colour change is produced when factor Xa (a serine protease enzyme) cleaves a synthetic 
substrate as one of the products of cleavage emits colour at a particular wavelength. The degree 
of colour change is measured spectrophometrically using a light sensor. As LMWH inhibits 
factor-Xa, the degree of colour change is inversely proportional to the activity or concentration 
of LMWH. Peak anti-Xa activity in vivo, is measured 3-4 hours after subcutaneous LMWH 
injection and the half life is 12 hours. Routine clinical monitoring of anti Xa levels in general is 
not recommended. However the indications for routine monitoring include pregnancy 
complicated by the presence of mechanical prosthetic heart valves. This is because of the 
physiological hypercoagulable state of pregnancy and the pharmacokinetics of LMWH during 
pregnancy in addition to the increased thrombogenicity conferred by the prosthetic valve. The 
clinical applicability of the anti-Xa test is still however a subject of debate. This is because the 
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correlation between various commercial assays is poor
44
. Secondly a large study randomizing 
surgical patients to receive prophylactic LMWH or UFH showed that there was no correlation 
between the anti-Xa level and bleeding and little correlation between the anti-Xa and 
thrombosis
45
. This study is quoted in an authoritative review on the guidelines for monitoring of 
LMWH therapy
46
.  
 
Cases of valve thrombosis occurred in the absence of anti-Xa monitoring in the unpublished 
HIP-CAT study
23
. This raised questions regarding the safety of LMWH. Additionally concerns 
were highlighted about possible teratogenicity of LMWH exposure in pregnancy. This resulted 
in a “warning” being issued by a LMWH manufacturer regarding the use of LMWH in pregnant 
women with mechanical prosthetic heart valves
47
. As LMWH does not cross the placenta, it is 
implausible that it causes foetal morbidity or mortality
37
. Subsequent to the warnings release, a 
cardiology consensus statement regarding the use of LMWH in pregnancy was issued stating it 
"should more appropriately
 
be considered an unproven and imperfectly studied alternative
 
among 
a trio of suboptimal and potentially unfavourable options
 
(warfarin, unfractionated heparin, low 
molecular weight heparins)"
 48
. A number of reviews have stated that there are presently no good 
data documenting the use of LMWH in pregnant women with mechanical prosthetic heart valves 
and there have been calls for appropriately designed studies to investigate this therapeutic option. 
One review concluded that LMWH could be the best option out of the three treatment options 
available but that all three options have still been understudied
48
. More recently, the earlier 
warning by the LMWH manufacturer has been rephrased to “use of Lovonox (LMWH) for 
thromboprophylaxis in pregnant women with mechanical PHV (prosthetic heart valves) has not 
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been adequately studied”49. The 8th American College of Chest Physicians (ACCP) guidelines 
recommend the use of LMWH at a dose aiming to achieve peak anti-Xa levels of ~1.0 U/ml as 
one of the treatment options
50
. 
Bridging therapy refers to a temporary interruption of long term anticoagulation, usually by 
replacement with another anticoagulant, for a specific procedure such as surgery. Intrapartum 
bridging therapy, in this context, refers to altering the anticoagulant protocol to allow for safe 
delivery. As such delivery should be free of bleeding while still providing anticoagulant cover in 
order to prevent thrombosis. In addition to LMWH, unfractionated heparin (UFH) has also been 
recommended as a drug for bridging therapy during delivery for this group of women
51
. One of 
the main advantages of UFH is that can be reversed if necessary by protamine sulphate, whereas 
the effects of LMWH cannot be easily reversed. However the less predictable pharmacokinetics 
and pharmacodynamics of UFH noted above consequently result in some less desirable effects of 
UFH when compared to LMWH.   
 
The use of LMWH in pregnancy may be affected by the specific pharmacokinetic profile in 
pregnancy. The pharmacokinetics of prophylactic fixed dose LMWH (enoxaparin) in pregnancy 
and post partum was assessed in a prospective study
52
. It was found that the volume of 
distribution of LMWH was lower in the post partum period compared to late pregnancy, the 
maximum concentration of LMWH was significantly higher post partum compared to late 
pregnancy and the renal clearance of LMWH was significantly decreased after delivery in 
compared to late pregnancy. The authors suggested that reducing the dose of LMWH may be 
required post delivery in order to prevent bleeding. 
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Due to the more predictable effects of LMWH, the indications for its use have continued to grow 
since its introduction. There are however still no guidelines on the use of LMWH for intrapartum 
bridging therapy in high risk pregnant women where the anti-Xa has been maintained at 1.0-1.2 
U/ml throughout pregnancy. This is due to the paucity of clinical data in this area. Bridging 
therapy guidelines are however available for non pregnant patients undergoing surgery
53
. These 
have been applied to pregnant women at delivery but the unique physiology and altered 
pharmacokinetics of LMWH in pregnancy
52
, especially for highly anticoagulated women, may 
ultimately expose these women to either bleeding or thrombosis. Studies are beginning to show 
that adjusted high dose LMWH therapy with monitoring may be efficacious for pregnant women 
at high risk of thrombosis, such as those with mechanical prosthetic heart valves
54
. As such a 
management protocol for the peripartum period should be designed to protect these maternal 
patients from both bleeding and thrombosis at this critical time.  
In light of the above it was decided to investigate the safety of adjusted dose enoxaparin for 
thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. 
 
 
 
 
 
 
 
 
19 
 
Objective: 
 
To determine whether the use of the LMWH, enoxaparin, is safe for pregnant women with 
mechanical prosthetic heart valves during pregnancy when used with dosage adjustment in order 
to maintain a peak anti-Xa of 1.0-1.2 U/ml. Key outcomes measured were prosthetic valve 
thrombosis, bleeding and maternal mortality.  
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Materials & Methods: 
This was a prospective observational study performed at Charlotte Maxeke Johannesburg 
Academic Hospital from 2007 to 2009. Our sample consisted of 15 consecutive pregnant 
women. Most of these women were either attending the anticoagulation clinic at Charlotte 
Maxeke Johannesburg Academic Hospital or Chris Hani Baragwanath Hospital for monitoring of 
warfarin therapy efficacy prior to conception.   
Inclusion criteria included the following: 
 Age between 18 and 49yrs 
 Carrier of a mechanical prosthetic heart valve in either the mitral or aortic position (single 
or double) 
 Written informed consent obtained prior to any protocol-specific procedures 
 Cardiac assessment where possible to confirm clinical stability 
 Ability to administer medication subcutaneously at home 
 Normal platelet count for pregnancy (>100x19^9/L) 
 
Exclusion criteria included the following: 
 Obstetric indications- namely the anticipated need for delivery in 2 weeks 
 Cardiac indications- namely infective endocarditis, very low ejection fraction 
 Known thrombophilia or thrombocytopaenia 
 Marked elevations of LDH level with clinical evidence of significant haemolysis 
 Anaemia (defined by Hb <8g/dL) 
 Active gastro-duodenal ulcer 
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 Patient involved in another clinical trial simultaneously  
 Severe hypersensitivity to low molecular weight heparin, warfarin or unfractionated 
heparin 
 Any condition that would make participation in the study impractical or is likely to be 
associated with non-compliance 
 
Indications for removal of patients from therapy included the following: 
 Non-compliance on treatment  
 Inability to administer medication at home 
 Development of thrombocytopaenia 
 Patients who require administration of  high molecular weight expanders such as dextran 
 
The following concomitant medications were not administered: 
 Any other anticoagulant drug 
 Any antiplatelet drug e.g. non steroidal anti-inflammatory drugs, dipyridamole with the 
exception 75-150mg of aspirin  
 Any medication which has interaction with LMWH or may interfere with evaluation of 
the clinical response (systemic glucocorticoids, ticlopidine, systemic salicylates, 
acetylsalicylic acid, thrombolytics and anticoagulants) 
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The experimental protocol observed was as follows. Women were admitted as soon as they 
discovered they were pregnant or whenever they presented to the hospital during pregnancy. All 
patients signed written consent to take part in the study.  
 
Baseline information collected form the patients comprised the mother’s age, demographics and 
previous medical history. The duration and type of anticoagulation in regard to the current 
pregnancy was recorded in addition to other medications being taken. Information pertaining to 
any previous clotting and bleeding was obtained. The women were asked about the underlying 
indication for valve replacement and problems relating to the mechanical heart valve since 
insertion. Patients were assessed in order to determine the New York Heart Association (NYHA) 
functional cardiac status. A full clinical examination followed including a haematological, 
cardiac and obstetric assessment. Baseline blood samples were taken for full blood count, 
differential blood count, renal function, liver function and blood type. 
 
Women were started at a dose of enoxaparin calculated at 1mg/kg twice daily. The dose of 
enoxaparin was then adjusted to achieve a peak anti-Xa level (three hours post dose) of greater 
than 1.0 U/ml and less than 1.2 U/ml. The women were taught how to inject themselves in the 
hospital. A transthoracic echocardiogram was performed to assess baseline cardiac function. 
Patients were then discharged home where they injected themselves twice a day (12 hourly) with 
enoxaparin until just prior to delivery.  
 
The women attended the ante-natal clinic weekly where they were asked about any overt 
bleeding, features of cardiac valve thrombosis such as chest pain and shortness of breath, as well 
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as symptoms of peripheral thromboembolic disease such as weakness. The mothers had a full 
clinical examination to assess for any bleeding, cardiac dysrythmias, congestive cardiac failure 
and neurological features of a cerebrovascular accident. Cardiac auscultation was performed to 
clinically assess valvular function.  
 
Blood was taken weekly for peak anti Xa levels in a 3.2% sodium citrate tube (dilution 1:10 in 
whole blood). The blood was then transported directly to the laboratory within an hour of 
collection form the patient. The anti-Xa level was measured at the NHLS (National Health 
Laboratory Service) Haematology Coagulation Laboratory at Charlotte Maxeke Johannesburg 
Academic Hospital. At each visit the dose of enoxaparin given the corresponding anti-Xa level 
for each patient was recorded. The dose of enoxaparin was adjusted weekly in order to maintain 
the therapeutic peak anti-Xa level of 1.0-1.2 U/ml for the duration of pregnancy. Anti-Xa values 
outside the target range would result in an either upwards or downwards adjustment in the dose 
of enoxaparin by 10mg.  
 
A transthoracic echocardiogram to exclude prosthetic valvular thrombosis was performed 
monthly. Valvular thrombosis was diagnosed by a suggestive history and clinical examination 
together with the following: observing a raised mean pressure gradient across the valve by 
transthoracic echocardiography; in the case of mitral valve thrombosis echocardiography may 
also detect a raised pulmonary artery pressure and right ventricular dysfunction; fluoroscopy 
would be performed to confirm valvular outflow obstruction by demonstrating reduced valvular 
leaflet movement. 
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All women were delivered while on LMWH therapy. Bleeding complications were noted using 
the standard bridging protocol for surgical procedures; the bridging regimen was subsequently 
adjusted to improve hemostasis as detailed below. The bleeding and thrombotic outcomes of the 
two LMWH bridging therapy regimens were then compared. 
 
LMWH Bridging Regimen 1: 
For the first seven consecutive women intrapartum bridging therapy was achieved by stopping 
the LMWH for at least 24 hours prior to delivery, unless the patient spontaneously went into 
labour. An intrapartum anti-Xa level was taken where possible, irrespective of mode of delivery. 
LMWH was restarted 12 hours post delivery. The initial postpartum dose was calculated as half 
the latest antepartum pre-delivery dose and the full antepartum dose was resumed thereafter. 
Anti-Xa levels were then monitored postpartum and the LMWH dose adjusted to achieve an 
Anti-Xa level of 0.8-1.0 U/ml. Bleeding was monitored clinically and by monitoring the patients’ 
hemoglobin levels. Warfarin therapy was started approximately two days post delivery and 
LMWH was stopped once a therapeutic INR was achieved (2.5-3.5). 
 
LMWH Bridging Regimen 2: 
Subsequently for 8 consecutive women intrapartum bridging therapy was achieved initially by 
stopping the LMWH. Serial anti-Xa level monitoring was then initiated beginning 8-12 hours 
after the last dose of LMWH. Delivery by Caesarean section or normal vaginal delivery was only 
allowed to occur when the pre-delivery anti-Xa had dropped to less than 0.5 U/ml (wherever 
possible), irrespective of the amount of time that had lapsed from the last LMWH dose. LMWH 
was restarted 12 hours after delivery at half the pre-delivery antepartum dose. This dose was then 
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adjusted to achieve an anti-Xa level of 0.8-1.0 U/ml. Women were kept on LMWH alone till 
about 1 week post delivery when warfarin therapy was added if no bleeding was present. 
Bleeding was monitored clinically and by monitoring the patients’ hemoglobin levels. LMWH 
was stopped once a therapeutic INR was achieved (2.5-3.5). 
 
“Major” bleeding was defined as bleeding resulting in a drop in the haemoglobin concentration 
by greater than or equal to 2g/dL or as bleeding requiring transfusion of at least two units of 
packed red blood cells. Bleeding not fulfilling these criteria was defined as “minor”.  
 
At birth, the babies had their sex and birth weight recorded. The birth weight was charted to 
determine the percentile according to gestational age at birth as per Lubchenco et al
55
. The babies 
were examined by a clinical geneticist or paediatrician to observe for clinical evidence of 
warfarin embryopathy. A whole body X-ray of the baby was also performed to detect epiphyseal 
stippling. The presence of typical clinical features or the observation of the radiological findings 
was defined as warfarin embryopathy.  
 
Maternal patients had a follow up transthoracic echocardiogram done post delivery and were 
discharged from the study on warfarin once the INR was therapeutic.  
 
Statistical analysis involved obtaining the average anti-Xa levels of all the patients each month 
and calculating the 95% confidence intervals. The average corresponding dose of enoxaparin 
required each month was also calculated together with the 95% confidence intervals. 
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The data was periodically reviewed by a data review and safety committee.  
 
A prospective control arm of pregnant women taking warfarin was not undertaken as we felt it 
was unethical to purposefully expose foetuses to a drug with known teratogenic potential. 
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Results: 
 
A total of 18 consecutive women met the inclusion criteria and consented to be part of the study. 
Two of these women were not included in the write up of this study as they were treated with 
adjusted dose enoxaparin therapy for two weeks or less before delivery. A further patient was not 
included in the write up of this study due to insufficient data.  Two of these patients did not 
develop any thrombotic or haemorrhagic complications during enoxaparin exposure in 
pregnancy. One patient developed haemorrhagic complications postpartum as outlined below. 
No patient who met the inclusion criteria declined to be part of the study. An additional patient 
with a mechanical prosthetic heart valve did not meet the inclusion criteria as she was less than 
18 years of age. 
 
Table 1 below illustrates baseline information of our patient group. 
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Table 1: Baseline Information 
Patient 
Number 
Mat age 
(yrs) Parity 
Other 
Medical 
Problems 
NYHA 
Class 
1 33 Multigravida Epilepsy 1 to 2 
2 18 Primigravida Nil 1 to 2 
3 24 Primigravida Nil 1 to 2 
4 32 Multigravida Nil 1 to 2 
5 20 Multigravida Nil 1 to 2 
6 40 Multigravida Nil 1 to 2 
7 28 Multigravida Nil 1 to 2 
8 22 Multigravida Nil 1 to 2 
9 23 Multigravida Nil 1 to 2 
10 32 Primigravida Nil 1 to 2 
11 27 Multigravida Nil 1 to 2 
12 21 Primigravida Nil 1 to 2 
13 31 Multigravida HIV 1 to 2 
14 23 Primigravida Nil 1 to 2 
15 21 Primigravida Nil 1 to 2 
 
 
  
The average age was 26.3 yrs (median 24 yrs); there were six primigravidas and nine 
multigravidas. One woman had epilepsy and was being treated with carbamazepine (patient 1); 
while another patient (patient 13) had HIV infection and was receiving antiretroviral therapy.  
 
Table 2 below shows the indication for valve replacement, the type, size and location of the 
prosthetic heart valve and the type and duration of anticoagulation given in pregnancy.  
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Table 2: Indication for and Duration of Anticoagulation 
Key-  MPHV = Mechanical Prosthetic Heart Valve 
 RHD = Rheumatic Heart Disease 
 MVR = Mitral Valve Replacement 
 AVR = Aortic Valve Replacement 
 
 
Patient 
Number 
Indication for 
LMWH 
Type of Mechanical 
Prosthetic Valve 
Prior Anticoagulation in 
Pregnancy 
LMWH Duration 
(Adjusted Dose) 
1 
Mitral & Aortic 
MPHV 2° to RHD   
MVR 27mm MIRA Edward, 
AVR 21mm MIRA Aortic warfarin week 1 – 17 week 18 - 38 
2 
Mitral MPHV 2° to 
RHD 29 mm St Jude Medical warfarin week 1 – 20 week 21 - 38 
3 
Mitral MPHV 
2° to RHD 27mm St Jude Medical 
warfarin week 1-4, fixed 
dose LMWH week 5-20 week 21 - 32 
4 
Mitral & Aortic 
MPHV 
2° to RHD 
MVR 27mm St Jude Medical, 
AVR 21mm St Jude Medical 
warfarin week 1-12, no 
anticoagulation week 13-
27 week 28-38 
5 
Mitral MPHV 2° to 
RHD 31mm MIRA 
warfarin week 
1 – 22 week 23 - 40 
6 
Mitral & Aortic 
MPHV 
2° to RHD 
MVR 27mm St Jude Medical, 
AVR 21mm St Jude Medical warfarin week 1 – 23 week 24 - 37 
7 
Mitral & Aortic 
MPHV 2° to RHD  
& Pacemaker 
MVR 29mm Mira, AVR 
19mm St Judes Regent 
no anticoagulation week 1 
- 22 week 23 - 39 
8 
Mitral MPHV 2° to 
RHD 
31mm Silzone St Judes 
Medical warfarin week 1-27 week 28-38 
9 
Mitral MPHV 2° to 
RHD 29mm Carbomedics Orbis warfarin week 1 – 10 week 11 – 38 
10 
Mitral MPHV 2° to 
RHD 27mm St Jude's Medical warfarin week 1-5 week 6 - 39 
11 
Mitral MPHV  
2° to RHD 33mm MIRA 
 
warfarin week 1-9 week 10 - 38 
12 
Mitral & Aortic 
MPHV 2° to RHD   
MVR 27mm Carbomedics 
Orbis, 
AVR 21mm Carbomedics Warfarin week 1 - 5 Week 6 - 38 
13 
Mitral MPHV 2° to 
RHD 33mm St Judes Medical Warfarin week 1-5 Week 6-38 
14 
Mitral & Aortic 
MPHV 2° to RHD   
MVR 27mm MIRA, AVR 
21mm MIRA Warfarin week 1-5 Week 6-36 
15 
Mitral MPHV 2° to 
RHD 
29mm Silzone St Judes 
Medical Warfarin week 1-4 Week 5 - 38 
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Six of the fifteen women had double prosthetic valves with an aortic MPHV in addition to a 
mitral MPHV. All the women had bileaflet mechanical prosthetic heart valves (second 
generation valves).  
 
Patient 4 previously had had one child and then had four previous miscarriages on warfarin 
therapy. Nine years prior to presentation she fell pregnant for the first time, while not on any 
anticoagulation and at eight months gestation developed valve thrombosis. She had an 
emergency valve replacement and caesarean section from which both she and her baby recovered 
well. Six years later she developed neurological features of thromboembolism (i.e. weakness) 
while not on any anticoagulation. She recovered from this with no overt long term sequelae. She 
did however develop a silent myocardial infarction which was discovered on enrolment into our 
study. Echocardiography revealed an old infarct on the anterior wall of the myocardium with a 
relatively good ejection fraction of 51%. She had no deterioration in cardiac function during her 
current pregnancy. 
 
Two women were not on any anticoagulation during pregnancy prior to presentation for 15 
weeks (patient four) and 23 weeks (patient seven). 
 
 
 
 
 
31 
 
Figure 1 below shows the duration of adjusted dose enoxaparin exposure relative to the duration 
of prior anticoagulation given in pregnancy. 
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Figure 1: Duration of Enoxaparin & Prior Anticoagulation in Pregnancy 
 
 
The average time to presentation to our unit and conversion to enoxaparin was 14.7 weeks 
(median 17 weeks). The total combined period of time that our women were exposed to adjusted 
dose enoxaparin during pregnancy was 344 weeks.  
 
Figure 2 below shows the average anti-Xa readings recorded throughout pregnancy with the 95% 
confidence interval.  
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Maintenance of the average anti-Xa between 1-1.2 U/ml throughout pregnancy was achieved 
successfully for this patient group. A higher anti-Xa level tended to be recorded as delivery 
approached.  
 
Figure 3 below shows the average enoxaparin doses in milligrams recorded throughout 
pregnancy with the 95% confidence interval.  
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This figure shows that the average dose of enoxaparin rose steadily throughout pregnancy. The 
total percentage increase in the average dose of enoxaparin given was 72.9%. The highest rate of 
change was noted just prior to and during the third trimester (after 27 weeks gestation). Of note, 
the range of the confidence intervals also grew throughout pregnancy, with the largest range 
recorded for 36-39 weeks.  
 
Table 3 below demonstrates antepartum adverse maternal outcomes. Maternal morbidity was 
expressed as valve thrombosis, bleeding and cardiac, obstetric or other complications. Maternal 
mortality is also recorded. 
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Table 3: Antepartum Maternal Morbidity & Mortality 
 
Patient 
Number 
Maternal Morbidity 
Maternal 
Mortality 
Valve 
Thrombosis Bleeding 
Cardiac/Obstetric/Other 
Complications 
1 Nil 
1 Episode spotting per 
vagina Nil Nil 
2 Nil Nil Nil Nil 
3 Nil Nil Nil Nil 
4 Nil Nil Nil Nil 
5 Nil Nil Nil Nil 
6 Nil Nil Nil Nil 
7 Nil Nil Nil Nil 
8 Nil Nil Nil Nil 
9 Nil Nil Nil Nil 
10 Nil Nil Nil Nil 
11 Nil Epistaxis  Itchiness at enoxaparin 
injection site 
Nil 
12 Nil Nil Nil Nil 
13 Nil Nil Left Arm Numbness Nil 
14 Nil Epistaxis Nil Nil 
15 Nil Nil Nil Nil 
 
 
None of the women developed prosthetic valve thrombosis during pregnancy and there was no 
maternal mortality.  
 
Patient 13 developed numbness and tingling of the left arm. This lasted about 6 hours and 
occurred at 19 weeks of gestation. On further enquiry it was revealed that she had suffered 
similar events since childhood prior to the insertion of the prosthetic valve. Echocardiography 
was carried out which revealed a normal functioning valve with no evidence of valvular 
thrombosis. A normal D-dimer level also confirmed the absence of thrombotic event. Her anti-
Xa level at the time was 1.18 U/ml. This episode did not recur during her pregnancy. 
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Patient 11 had four episodes of epistaxis while on enoxaparin in this pregnancy. She presented 
with a history of epistaxis since childhood. Each episode of epistaxis in this pregnancy involved 
the left nostril (this was the same nostril from which she had had a long history of bleeding) and 
occurred when the ambient temperature was high. The severity of the bleeding varied from a few 
drops to an episode which required nasal packing with gauze soaked with zinc oxide paste in the 
casualty department. However the patient did not fulfil the criteria for major bleeding. A peak 
anti-Xa taken soon after presentation revealed an anti-Xa of 1.35 U/ml, mildly greater than the 
therapeutic range. She was subsequently treated with saline nasal drops and chloramphenicol 
ointment and her enoxaparin dose was adjusted downwards to return into the therapeutic range. 
This patient developed mild itching at the site of enoxaparin injection. This may have 
represented a mild allergy to the drug. This was treated with a topical antihistamine ointment 
with some improvement. Patient 15 had no previous history of epistaxis however developed an 
episode of epistaxis during her pregnancy. The bleeding was defined as minor, however she 
required nasal packing. A peak anti-Xa revealed a result of 1.79 U/ml at the time of bleeding. 
Her dose of enoxaparin was reduced in order to achieve the target anti-Xa level. She did not have 
any further epistaxis during her pregnancy. One woman developed spotting with a few drops of 
blood passed per vagina (patient 1). No other potential side effects of enoxaparin use were noted 
such as heparin induced thrombocytopaenia or alopecia and there was no clinical evidence of 
vertebral osteoporosis, however no bone mineral density studies were performed. 
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Tables 4 and 5 pertain to the intrapartum and postpartum obstetric outcome. All blood 
transfusions given are recorded below. No patient developed thrombocytopaenia in either the 
antepartum or post partum periods. 
 
 
 
Table 4: Peripartum Obstetric Outcome LMWH Bridging Therapy Regimen 1 
Key-  MPHV = Mechanical Prosthetic Heart Valve 
 
Patient 
No 
Mode of 
delivery 
Predelivery 
Dose of 
LMWH 
(mg, bid) 
Intrapartum 
Anti Xa 
(U/ml) 
Intrapartum 
Estimated 
Blood Loss 
Postpartum 
Complications 
Maternal 
Mortality 
1 
NVD - 
vacuum 
assisted & 
episiotomy 150 1.26 300ml 
major bleed 
from 
episiotomy site Nil 
2 
c/section for 
fetal distress 160 n/a 300ml 
minor bleed 
into antecubital 
fossa post 
phlebotomy Nil 
3 
elective 
c/section for 
IUGR & 
Oligohydra
mnios 90 0.8 +/-600ml 
minor bleed 
from operation 
incision site Nil 
4 
elective 
c/section for 
1 prev 
c/section 150 0.41 800ml 
major bleed 
into uterine 
broad ligament, 
hematoma 
measured +/-
10cm in 
diameter Nil 
5 NVD - BBA 100 >0.66* 
n/a, on arrival 
bleeding per 
vagina 
major bleed 
into perineum 
and vaginal 
wall at 
laceration site Nil 
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The average antepartum dose of LMWH just prior to delivery was 130 mg bid. All the women in 
LMWH Bridging Regimen 1 bled. The average anti-Xa level at the time of delivery was 0.75 
U/ml. The average estimated intrapartum blood loss was 500ml. Blood transfusions given are 
recorded below and no patient developed thrombocytopaenia in either the antepartum or post 
partum periods. 
 
There were three major bleeds (60%) and two minor bleeds (40%). One patient who presented in 
the initial phase of the study but was excluded from the overall study, developed hemorrhagic 
complications postpartum. She was excluded from the study because she was converted to 
adjusted dose enoxaparin less than 2 weeks prior to delivery due to late presentation. She was a 
23 yr old lady, P0 G2, with a mitral mechanical prosthetic heart valve. She had a cesarean 
section for failed induction. She was on 140mg bid of enoxaparin just prior to delivery and had 
an intrapartum anti-Xa level of 0.82 U/ml. The estimated blood loss during the cesarean section 
was 700ml. Haemostasis at the time of performing the Caesarean section was described as easy. 
She developed a non-fatal major bleed a few hours postpartum. 2.5L of serosanguinous fluid was 
drained from peritoneum on re-laparotomy 8 hours post delivery. She subsequently recovered 
after receiving a total of 6 units of pure red blood cells within 1 week.  
 
Patient 5 went into spontaneous labour at home a few hours after having been seen at the clinic 
in hospital that morning. She had a precipitous labour and was not able to get to the hospital 
before delivery. On that morning, she visited the clinic, where her peak anti-Xa was 1.0 U/ml. 
She delivered 12 hours later and a further 12 hours after delivery her anti-Xa was still 0.66 U/ml, 
suggesting that her anti-Xa at time of delivery was in between these two values at delivery. On 
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arrival to hospital, she was bleeding from a vaginal laceration which was sutured. Three days 
after delivery while on LMWH therapy a perineal hematoma became clinically evident at the 
vaginal laceration site which extended up the posterior vaginal wall. On the day the perineal 
hematoma was first noted her peak anti-Xa was 1.38 U/ml. This hematoma was incised in theatre 
after which the patient recovered, however the patient had required 4 units of pure red blood 
cells. 
 
Patient 4 had an anti-Xa of 0.41 U/ml at time of Caesarean section and showed no evidence of 
bleeding during the first 24 hours post delivery. However soon after resuming the pre-delivery 
doses of LMWH therapy, she developed a large hematoma in the broad ligament measuring 
10cm in diameter. She required two re-look laparotomies which ended in a subtotal hysterectomy 
and required a total of 10 units of pure red blood cells, which were given within 1 week, prior to 
her recovery. 
 
Patient 1 had an intrapartum anti-Xa of 1.26 U/ml. She developed recurrent bleeding from the 
site of an episiotomy which would occur two days after the addition of warfarin to LMWH 
therapy, for conversion to oral anticoagulation. The first bleeding episode began four days post 
delivery. Warfarin therapy would then be withheld and the bleeding would slowly subside, but 
two days after reintroduction of warfarin therapy the bleeding would resume. In the interim the 
patient would receive transfusions of pure red blood cells as needed. The timing of the bleeding 
appeared to coincide with the addition of warfarin therapy while the patient was already over 
anticoagulated as documented by anti-Xa levels of greater than 1.5U/ml (highest 1.75 U/ml). 
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INRs done at the time of bleeding were all normal. In total the patient received 16 units of pure 
red blood cells over a 3 week period before the bleeding subsided. 
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Table 5: Peripartum Obstetric Outcome LMWH Bridging Regimen 2 
Patient 
No 
Mode of 
delivery 
Pre-delivery  
Dose of LMWH 
(mg, bid) 
Pre-delivery 
Anti Xa 
(U/ml) 
Intrapartum 
Estimated Blood 
Loss  
Postpartum 
Complications 
Maternal 
Mortality 
6  NVD 90 0.46 250ml 
Minor Bleed 
Passed clot PV 
during labour  Nil 
7 
c/section 
for failed 
induction 140 0.33 500ml Nil Nil 
8 
c/section 
for 1 prev 
c/section 120 0.06 800ml Nil Nil 
9 
c/section 
for 1 
previous 
c/section 130 0.4 650ml 
discovery of 
valvular 
pannus  Nil 
10 
c/section 
for failed 
induction 80 0.17 600ml Nil Nil 
11 
NVD with 
superficial 
laceration 90 0.3 300ml Nil Nil 
12  
NVD - 
vacuum 
assisted 
with 
episiotomy 100 0.22 
300ml 
 
Minor Bleed 
trace hematuria 
 Nil 
13 
c/section 
failed 
induction 70 0.17 650ml Nil Nil 
14  
nvd with 
episiotomy 
 130 0.11 
350ml 
 
Major Bleed  
episiotomy site  Nil 
15  NVD 90 0.17 +/- 450ml Nil Nil 
Key-  MPHV = Mechanical Prosthetic Heart Valve 
- mg = milligrams 
- bid = twice daily 
- PV = per vagina 
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The average antepartum dose of LMWH just prior to delivery was 104 mg bid. The average anti-
Xa level prior to delivery was 0.24 U/ml. The estimated average blood at delivery loss was 
485ml.  
 
Three of the women in the LMWH Bridging Regimen 2 cohort (12.5%) developed bleeding. One 
major bleed was recorded in patient 14 who bled from an episiotomy site, this occurred 4 days 
post delivery. She recorded a drop in her hemoglobin from 13.2g/dL post partum to 10.4g/dL 
after the bleeding episode and did not require transfusion of pure red blood cells. Two minor 
bleeds were recorded. Patient 6 accidentally received a prophylactic dose of enoxaparin 
intrapartum, during prolonged labour, and subsequently passed a clot per vagina with no other 
clinical sequelae. Patient 12 developed a trace of blood in the urine post delivery, possibly due to 
a prolonged second stage of labour with foetus pressing on the bladder. The hematuria became 
microscopic within 24 hours and no further gross hematuria occurred despite continuation of 
anticoagulation. The microscopic hematuria resolved completely after a few days. 
 
No valvular thromboses were found on final transthoracic echocardiography while on enoxaparin 
post delivery. Patient 9 developed asymptomatic pannus which was detected post delivery by 
echocardiography. She subsequently also developed valvular thrombosis on the same valve 4 
weeks later, which was associated with significant dyspnoea. This occurred 2 days after the 
enoxaparin was stopped, despite the patient being therapeutic on warfarin therapy at the time (6 
weeks post partum). She had an uneventful valve replacement.  
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There was no cardiac decompensation noted in either the antepartum or postpartum periods in 
any of the patients. 
 
Table 6 below outlines the details pertaining to foetal outcome. 
 
 
Table 6:  Foetal Outcome 
 
Patient 
No 
Foetal 
Sex 
Birth 
Weight 
Birth-
weight 
Percentile 
Gestational 
age at 
birth 
Congenital 
Malformations 
Foetal 
Mortality 
1 F 3182g >10
th
 38 Nil Nil 
2 F 2590g >10
th
 38 Nil Nil 
3 F 1750g >10
th
 32 Nil Nil 
4 M 3150g >10
th
 38 Nil Nil 
5 M 3450g >10
th
 40 Nil Nil 
6 M 2600g >10
th
 37 Nil Nil 
7 M 2700g >10
th
 39 Nil Nil 
8 F 3060g >10
th
 38 
Hypoplastic 
toenails Nil 
9 M 2180g <10
th
 38 
Small convex 
toenails Nil 
10 M 3240g >10
th
 39 Nil Nil 
11 M 2240g <10
th
 38 
Multiple 
Abnormalities* Nil 
12 M 2800g >10
th
 38 Nil Nil 
13 F 2700g >10
th
 38 Nil Nil 
14 M 2700g >10
th
 36 Nil Nil 
15 F 2280g <10
th
 38 Nil Nil 
 
* See text for details 
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There was no foetal mortality. The average foetal birth weight was 2708g. There were 3 babies 
born with intrauterine growth retardation (patients 9, 11, 15). The baby born to patient 11 was 
exposed to warfarin in utero until the 9
th
 week of gestation. He had a slightly flat nasal bridge 
and had respiratory distress after delivery, mild micrognathia, unusual ears with overfolded 
helices superiorly but unfolded helices posteriorly, low set and posteriorly rotated ears, diastasis 
recti, mild brachydactyly of his fingers with convex fingernails, absent 5th toenails with 
hypoplastic toenails on toes 1 to 4. None of the X-rays done on any of the babies showed any 
epiphyseal stippling.  
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Discussion 
 
Pregnancy for a woman with a prosthetic heart valve poses risks to both her and her unborn 
child. It has appropriately been called a “double jeopardy” situation as these mothers are 
vulnerable to valve thrombosis due to treatment failure and the foetus may be exposed to 
potentially teratogenic anticoagulant therapy.  
 
The use of LMWH in these women has been a subject of much controversy. This is because 
there are numerous cases and case series reporting valve thromboses in pregnant women with 
mechanical prosthetic heart valves treated with low molecular weight heparin. In the absence of 
randomized controlled trials, treatment decisions have been based on these anecdotal reports or 
on reviews of the literature. Two such reviews received acceptance. The first was a review of 81 
pregnancies in 75 women with mechanical prosthetic heart valves treated with LMWH during 
pregnancy done by Oran et al
56
. This study reported an 8.6% rate (7/81) of valve thrombosis and 
a 12.35% rate (10/81) of thromboembolic complications. 51 of these pregnancies were associated 
with anti-Xa monitoring, and in only one of these monitored pregnancies was a thromboembolic 
phenomenon recorded. This nonfatal case of valve thrombosis was associated with a sub 
therapeutic peak anti-Xa level of 0.62 U/ml at the time (20 weeks gestation). It was however 
complicated by the fact that the patient had initially presented at 8 weeks pregnant with an atrial 
clot which had resolved two weeks after starting LMWH at 1mg/kg before the thrombotic 
reoccurrence
57
. The second review by James et al
58
 similarly identified cases of low molecular 
weight heparin used for thromboprophylaxis for pregnant women with mechanical prosthetic 
heart valves. Of the 76 cases reviewed, 22% (17/76) were associated with thrombotic events. 
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Thirteen cases were valve thromboses, of which two were fatal from the HIP-CAT study
23
. The 
HIP-CAT study was a randomized controlled trial comparing enoxaparin (1mg/kg twice a day) 
throughout pregnancy to a regime consisting of UFH followed by warfarin. LMWH dosage 
adjustment was not performed.  
 
It is possible that the rates of valve thrombosis quoted in the reviews above may represent an 
overestimate, given that cases are more likely to be written up and accepted for publication if a 
potentially catastrophic event took place. Despite the possible bias, the rates of valve thrombosis 
quoted are unacceptably high, especially as valve thrombosis in these women is often associated 
with maternal and foetal mortality. Careful review of the cases of valve thrombosis reported by 
both studies however indicated a consistent pattern; most, if not all of these cases were 
associated with an inadequate dose of LMWH, lack of monitoring, or sub therapeutic anti-Xa 
levels. These reports of valve thrombosis and deaths in the absence of monitoring of anti-Xa 
levels are a strong indication that monitoring is necessary for a good outcome of these patients. 
When the subset of patients reported by Oran et al
56
 who were not monitored by anti-Xa levels is 
analysed, 30% (9/30) were associated with thromboembolic complications. Additionally a study 
done by Barbour et al has demonstrated that based on monitoring of the anti-Xa level, the 
requirements of LMWH increased during pregnancy in 85% of the women studied
59
. For these 
reasons, monitoring of anti-Xa levels was performed weekly in our study, and the dose of 
LMWH was subsequently adjusted in order to maintain the high level of anticoagulation required 
to keep the anti-Xa at 1.0-1.2 U/ml throughout pregnancy. Our results show that the average 
peak anti-Xa level was well maintained in the target range throughout pregnancy. Additionally 
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the confidence intervals appeared relatively well controlled showing that large variations in the 
anti-Xa levels were not a finding in this study. 
 
Increasing doses of enoxaparin were required for our patients studied. The initial average dose 
progressively increased by 72% till the highest average dose was recorded at 36-39 weeks. The 
increased requirements of enoxaparin may be explained by a number of reasons. One possible 
reason could be that the increasing dosage mirrors the increasing thrombogenicity that occurs 
during pregnancy due to the documented increase in the concentration of coagulation factors and 
the suppression of anticoagulation and fibrinolysis
1, 3,4
. Another possibility could be that the rise 
in the average dose was a reflection of weight gain occurring in pregnancy. This would need to 
be verified by further studies. Higher confidence intervals of the average dose of enoxaparin 
were recorded in the final two average readings in the third trimester. This coincided with a 
higher average anti-Xa level recorded for the same period. These two observations may be 
explained by the drop in the glomerular filtration rate occurring towards the end of the third 
trimester. This could have resulted in reduced clearance of enoxaparin during this period hence 
higher concentrations and a greater predisposition to bleeding. This hypothesis has been proven 
by a study done by Casele et al
52
. This was a prospective study done to observe the 
pharmacokinetics of prophylactic fixed dose LMWH (enoxaparin) in early pregnancy (12-15 
weeks), later in pregnancy (30-33 weeks) and postpartum. It was found that the renal clearance 
was significantly lower later in pregnancy compared to earlier in pregnancy and that the 
concentration of LMWH 12 hours post dose was significantly higher later in pregnancy 
compared to earlier in pregnancy. 
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Our data show that appropriate adjusted dose enoxaparin may be efficacious in the prevention of 
cardiac valve thrombosis in this high risk group of women. A similar finding has been shown by 
two other studies also performed in maternal patients with mechanical prosthetic heart valves in 
New Zealand
54
, England
60
 and Norway
61
. The New Zealand study used adjusted dose enoxaparin 
therapy to achieve a peak anti-Xa of 0.7-1.2 U/ml at four hours post dose. This was a large study 
(n=47) which showed a 10.6% rate of valve thrombosis related to enoxaparin therapy. The 
reasons outlined for valvular thrombosis were sub-therapeutic anti-Xa levels and poor 
compliance. The English study used adjusted dose dalteparin and enoxaparin in order to achieve 
a peak anti Xa of 1-1.2 U/ml throughout pregnancy 4 hours post dose. This study showed an 
8.3% (1/12) rate of valve thrombosis. The reason stated for this was that the patient had a sub 
therapeutic anti-Xa level and frequent monitoring of the anti-Xa was not possible. A further 
complicating factor was that this patient also had an underlying thrombophilic state 
(heterozygous prothrombin G20210A gene mutation). It is not clear though how often patients 
had anti-Xa monitoring in this study.  
 
The Norwegian study was a retrospective review of 12 patients with mechanical prosthetic heart 
valves treated with LMWH throughout pregnancy with dosage adjustment in order to achieve a 
target peak anti-Xa of 0.7-1.2 U/ml at 3-4 hours post dose (with the exception of the first two 
patients in whom the target peak anti-Xa was 0.4-0.8 U/ml). Patients were initially monitored 
fortnightly till a therapeutic anti-Xa was achieved, then monthly thereafter. One patient 
developed aortic valve thrombosis while another developed thromboembolism in the left leg. 
The reason given for thrombosis in these patients was a low dose of LMWH (dalteparin). It is not 
clear what the anti-Xa levels were at the time of thrombosis. A possible reason why the rate of 
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valvular thrombosis observed in our study was lower than that observed in these studies could be 
that there was a higher target range for the peak anti-Xa in our study in comparison to the New 
Zealand and Norwegian studies. This is especially so given the findings of Barbour et al who 
demonstrated that peak levels between 0.5-1.0U/ml were associated with trough levels of <0.5 
U/ml in the great majority of cases
59
. Another possible reason for the lower rate of 
thromboembolism found in our study could be that more frequent anti-Xa monitoring was 
performed in our study (weekly as opposed to monthly). Both these factors could have reduced 
the likelihood of our patients developing sub therapeutic anti-Xa levels and subsequent valve 
thrombosis. Trough anti-Xa levels were however not measured in our study and there is currently 
no good data to show how frequently anti-Xa levels should be monitored for this patient group. 
More frequent antenatal visits may have also helped with patient compliance. The limitations of 
our study though are that there was no control group and it was not composed of a large sample 
size. The results of these studies would support the recommendation of the 7
th
 ACCP 
guidelines
51
 in which adjusted dose LMWH is recommended as treatment option for this patient 
group in order to achieve a peak anti-Xa of 1-1.2 U/ml. This is as no patients developed valvular 
thrombosis on enoxaparin while the anti-Xa was in this therapeutic range. 
 
A few of our patients were at risk of thromboemboloic disease for inadequate therapy prior to 
presentation. Patient 3 was on fixed low dose LMWH from the fifth week of gestation till week 
20, prior to presentation. This woman had a normal functioning valve when echocardiography 
was performed at presentation. Patients 4 and 7 were not on any anticoagulation for significant 
periods of time (15 and 23 weeks respectively). Patient 4 had a long term history of non 
compliance on warfarin which may have contributed to her decision to stop taking warfarin after 
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the 12
th
 week of pregnancy. Patient 7 had not received enough education about her condition to 
understand the necessity of taking anticoagulation. These patients exposed themselves to the risk 
of developing serious thromboembolic complications. One study showed a 25% risk of 
developing thromboembolic complications if either no treatment was given or only antiplatelet 
therapy with aspirin was offered
23
. The compliance of both of these patients however once 
enrolled on the trial was excellent. 
 
All the women on our study had second generation prosthetic valves. Despite still being high 
risk, they are at a lower risk than the group of women with older generation prosthetic valves in 
the mitral position
19
. The 8
th
 ACCP guidelines recommend that these highest risk patients be 
treated with warfarin throughout pregnancy with replacement by adjusted dose UFH or LMWH 
closer to delivery
50
. Appropriate studies are therefore required to assess the efficacy of LMWH 
in pregnant women with first generation prosthetic valves. Due to their greater thrombogenicity 
however, these first generation prosthetic valves are no longer as commonly used as the second 
generation prosthetic valves in our centre.  
 
Bleeding post delivery while on LMWH therapy is not a common problem reported in the 
literature. In one review of 41 pregnancies by Dulitzki et al, no significant bleeding problems 
were encountered at delivery for women taking prophylactic doses of LMWH or weight based 
treatment doses of LMWH
62
. This was confirmed by another study which showed that 
peripartum bleeding complications were not increased in 55 women taking prophylactic or 
treatment doses of LMWH compared to a matched control group not on any anticoagulation
63
. A 
possible explanation as to why significant peripartum bleeding was not encountered in the 
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women described in these studies is that most of these women were not as highly anticoagulated 
as those requiring maintenance of the anti-Xa between 1.0-1.2 U/ml. One study done in pregnant 
women with mechanical prosthetic heart valves treated with adjusted dose enoxaparin to achieve 
an anti-Xa level of 0.7-1.2 U/ml, showed a postpartum bleeding rate of 32%
9
. An issue further 
compounding the analysis of bleeding complications for patients on LMWH therapy is the 
controversy surrounding whether there is a correlation between the anti Xa level and clinical 
outcome. All the women on LMWH Regimen 1 bled around the time of delivery. This may have 
occurred as a result of a number of reasons, as outlined below.  
 
A few hours post Caesarean section, the 23 yr old patient, excluded from the overall study, was 
discovered to have a significant bleed into the peritoneal cavity. Haemostasis at time of 
performing the Caesarean section was however described as easy and the blood loss during the 
procedure was within expected limits for non-anticoagulated women. This clinical picture of 
delayed bleeding is in keeping with a coagulation factor deficiency dependent type bleed. This is 
consistent with the mechanism of action of LMWH namely factor Xa inhibition via 
antithrombin. Hence the finding of an intrapartum anti-Xa of 0.82 U/ml in a patient who went on 
to bleed suggests, that for this woman, the anti-Xa was too high for delivery by Caesarean 
section and she may have fared better if anti-Xa was lower. Furthermore bleeding occurred 
despite the fact that surgery was performed 30 hours after the last dose of LMWH was 
administered; hence she was not protected from bleeding by waiting for 24 hours after receiving 
the last dose of LMWH. 
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In patient 5 the cause of the perineal hematoma appeared to be twofold. Firstly her anti-Xa may 
have been too high at time of delivery. Secondly, post delivery she seemed to develop a major 
bleed which was associated with a high peak anti-Xa of 1.38 U/ml on the day of the bleed. Her 
subsequent cause of bleeding appeared to be excessive anticoagulation post delivery despite 
aggressive anti-Xa monitoring and downward dosage adjustment. The same pattern of delayed 
onset major bleeding a few days post delivery, despite the same intensive monitoring and dose 
adjustment, was also noted for patient 4. Hence for patients 4 and 5 the resumption of pre-
delivery doses of LMWH after delivery seemed to be associated with significant bleeding. 
Patient 1 however, who delivered vaginally, had no evident bleeding for the first 48hours despite 
having the highest anti-Xa at time of delivery of 1.26 U/ml. For this woman the timing of the 
bleeding seemed to coincide with the introduction of warfarin while highly anticoagulated on the 
enoxaparin. 
 
None of the women in the Regimen 2 group developed major bleeding immediately post partum. 
Delivery at an average anti-Xa level of 0.75 U/ml in Regimen 1 was associated with a greater 
risk of developing bleeding immediately post partum. Due to the altered renal and cardiovascular 
changes in pregnancy, empirically waiting 24 hours from the last LMWH dose before delivery 
did not protect our women from bleeding. As shown in the Regimen 2 group, allowing the anti-
Xa level to guide the time of delivery resulted in a favourable bleeding outcome. The average 
pre-delivery anti-Xa level found in this group was 0.24 U/ml. Hence attaining an appropriate 
anti-Xa level prior to delivery may allow for safer delivery of these women. 
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Upon resumption of pre-delivery doses 24 hours post delivery women had a tendency to bleed. 
We also found that it was very difficult to attain the target anti-Xa post delivery in the LMWH 
Bridging Regimen 1 group for about a week after delivery despite daily anti-Xa monitoring and 
aggressive subsequent dosage adjustment. These bleeding events are however, in keeping with 
the findings of Casele at al. They found that immediately post delivery the renal clearance of 
LMWH decreases sharply. This is also associated with a smaller volume of distribution for the 
drug. The factors combine to create comparatively greater peak concentrations of LMWH post 
delivery compared to pre-delivery
52
. If the same pre-delivery dose is given postpartum, greater 
LMWH peak concentrations result in over-anticoagulation followed by an increased propensity 
to bleed. 
 
The lower rate of bleeding in LMWH Bridging Therapy Regimen 2 is encouraging, however the 
risk of thrombosis in these women should still be considered. None of the women displayed 
clinical features of valvular thromboembolic disease in the postpartum period prior to discharge 
on warfarin with therapeutic INR’s. Despite its less predictable pharmacokinetics than LMWH, 
UFH has been used with success as intrapartum bridging therapy. A prospective trial comparing 
the use of UFH to an appropriate LMWH regimen for highly anticoagulated pregnancies may be 
of benefit in finding the safest mode of delivery for these women. When using intravenous UFH 
for bridging therapy, the practice of stopping this therapy 4-6 hours prior to surgery or immediate 
reversal with protamine sulphate may be used. On this regime the woman will be protected from 
bleeding but will not have any thromboprophylactic cover. This is contrasted to delivery on 
LMWH at an appropriate anti-Xa, possibly 0.5-0.2 U/ml, which would still provide a degree of 
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thromboprophylaxis until the next LMWH dose. The use of LMWH may thus be especially 
useful in these women in also protecting against the risk of thrombosis. 
 
For a safe regimen for intrapartum bridging therapy using LMWH for women maintaining an 
anti-Xa of 1.0-1.2 U/ml the bridging protocol would need to strictly be adhered to, and may 
include the following aspects: women should be delivered when their anti-Xa is less than 0.5 
U/ml as opposed to waiting for a prescribed 24 hour period; post delivery, half the pre-delivery 
dose should be given and that dose adjusted according to the anti-Xa level with the aim of 
maintaining a target anti-Xa value of 0.8-1.0 U/ml; warfarin therapy should be delayed for at 
least a week post delivery. These findings would need to be confirmed by a prospective study 
with a larger sample size. 
 
Warfarin therapy for pregnant women with MPHVs is efficacious in the prevention of cardiac 
valve thrombosis with the reported overall maternal mortality reported as 2.9%
23
. In keeping 
with this, none of the women developed valvular thrombosis while on warfarin therapy. Until a 
randomized controlled study is done do compare the use of adjusted dose enoxaparin to warfarin 
it will be difficult to say that enoxaparin is at least as efficacious as warfarin in the prevention of 
maternal thromboembolic disease in this patient group. A prospective study such as this would 
be difficult to perform, and probably unethical, given the risk of warfarin embryopathy. Studies 
are however beginning to show that adjusted dose enoxaparin may have a significant role to play 
for these patients in both maternal thromboprophylaxis as well as the prevention of foetal 
morbidity and mortality related to oral anticoagulant use. 
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Maintenance of the anti-Xa at 1.0-1.2 U/ml throughout pregnancy results in a high degree of 
anticoagulation, thus a higher theoretical risk of bleeding. Using the anti-Xa as a predictor of 
bleeding has been disputed by some authors. The large studies that have found no correlation 
between anti-Xa levels and the risk of bleeding (or thrombosis), were either not based on 
pregnant patients
45
, or actively excluded pregnancy
64
. This is especially so given the changes in 
the pharmacokinetics of LMWH occurring during pregnancy
52
. The patients in these studies 
were also either on prophylactic fixed dose LMWH
45
 or had a lower target peak anti-Xa (0.3-0.9 
U/ml)
64
. Contrastingly, our findings show that the two patients who developed epistaxis did so 
when their ant-Xa levels were greater than the therapeutic range. One of the two women with 
epistaxis already had a predisposition to nose bleeding which was exacerbated by the enoxaparin. 
None of the women in our study developed major bleeding requiring transfusion of as a 
complication of enoxaparin therapy during their pregnancy. The general lack of bleeding in the 
antepartum period is a positive finding which further supports the use of enoxaparin in the 
women studied. However as the use of adjusted dose enoxaparin for pregnancies at high 
thrombotic risk begins to gain favour, the risk of bleeding during the peripartum period should be 
highlighted. The clinical utility of the anti-Xa test, especially at high anti-Xa levels of 1-1.2U/ml, 
requires further investigation in pregnancy. 
 
The overall foetal outcome was relatively good. The baby born to patient 1 had multiple 
congenital abnormalities. A paediatric geneticist with an interest in warfarin embryopathy 
examined the baby, and concluded that while the diagnosis of warfarin embryopathy was indeed 
possible, an underlying genetic abnormality could not be excluded. Interestingly, the mother also 
had a flat nasal bridge without being exposed to warfarin in utero herself. Two other babies (of 
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patients 8 and 9) had mild features which have previously been described as being due to 
intrauterine warfarin exposure. They did not have any other clinical features of warfarin 
embryopathy. The fact that the average time to presentation at our clinic was at least 2 weeks 
after the period of embryogenesis is concerning.  Possibly, as the use of adjusted dose 
enoxaparin based on anti-Xa monitoring for this patient group becomes more publicised, this 
may increase the awareness of this alternative therapy among both physicians and patients. This 
may result in earlier referrals before the critical sixth week of gestation. Emphasis must be 
placed on frequent testing for pregnancy and on conversion to enoxaparin no later than upon 
earliest discovery of pregnancy. 
 
The rate of improvement of the socioeconomic living conditions of the majority of people in 
developing countries, such as South Africa, is slow. Hence it is unlikely that the prevalence of 
rheumatic heart disease in such nations will drop significantly in the near future. More female 
adolescents and adults continue to require valve replacements due to rheumatic heart disease. 
Showing that enoxaparin may be administered safely to them when pregnant, without posing a 
significant risk to either mother or baby, would be of value to these patients. It would also serve 
to support the further use of the more durable mechanical prosthetic heart valves for this group of 
patients. 
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Conclusion 
Our data show that enoxaparin may be administered safely in pregnant women with mechanical 
prosthetic heart valves when there is dosage adjustment throughout pregnancy in order to 
maintain an anti-Xa of 1.0-1.2 U/ml. Women with a significant bleeding tendency from prior to 
starting anticoagulation should be monitored closely to exclude bleeding as a complication of 
LMWH therapy. 
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